Download presentation
Presentation is loading. Please wait.
1
Thyroid
2
Physiology Seretion of thyroid hormones – T3, T4, calcitonine
Iodine: 100 microgrames; 30% absorbed in digestive tract Capture in thyroid gland – oxidation (peroxidaze) – transportation in coloid (thyroglobuline) – iodisation of thirozine – MIT, DIT –T3, T4 – blood stream
3
Thyroid hormones Increase O2 consumption and metabolism
Proteic metabolism: increase catabolism and anabolism (groth and development) Lipid metabolism: mobilization of lipids from fatty tissue and stimulates oxidation at cellular level. Glucidic metabolism: hyperglicemia (sinergistic with adrenaline - β-receptori), diabetes: newly developed or worsening Essential for the normal brain development (stimulated myelin production and neuronal ramifications) idiotism. Excess of T3 and T4 – thyrotoxicosis
4
Hyper Hypo Protidic metabolism
Catabolism – loss of weight and muscular tissue Pozitiv nitrogen balance but with anabolism Lipidic metabolism Low cholesterol and TG High cholesterol- ateroscolerosis Gucidic metabolism Hyperglicemia Low intestinal absorbtion H2O electolites Edema Water retention and depolimerization of MPZ = mixedema Basal metabolism Increase = heat production Decereased Cardiovascular Hyperkinesia Deceresed cardiac output (mixedematous infiltration of myocardial muscle) Nervous system Hyperexcited, nervousness, insomnia Apatie, lentor, coma Digestiv Diharrea Constipation
5
GOITER ANY increase of volume Associated with : Benign Malignant
Normal Hyper-function Hypo- function
6
Goiter structural changes in thyroid gland generated by the incapacity to inssure a normal plasmatic level of thyroid hormones A. Familial goiter – geneti factors, many mambers on the same family B. Endemic goiter – a significant number of cases in the same arrea – low iodine in the environment C. Sporadic – not always a clear cause.
7
Iodine deficit in thyroid gland
Deficit in synthesis or hormon excretion (normal iodine or excess of iodine) Increased hormonal needs Lack of iodine in water Lack of intake Abnormal absorbtion Excessive loss (diarrhea, breast feeding) Blocked transmembrane transport of Iodine (perclorate, thyocianate intoxication) Genetic factors (under evaluation) Iatrogenic (long term iodine, AINS, corticoids, synthetic antithyroid drugs) Endoscrine diseases (acromegaly) Menopause Puberty/Pregnancy/Stress
8
Pathology Difuse goiter Nodular goiter Adenomatous goiter
Coloidal goiter Cystic goiter Vascular goiter Fibrotic goiter Calcified goiter
9
GOITER VOLUM TOPOGRAFY Pathological characteristic CONSISTENCE
whole/lob/istm Pathological characteristic Nodular, vascular, cystic.. CONSISTENCE Elastic, soft, hard MOBILITY ASSOICIATED LN
10
Clinical Signs HYPO HYPER Skin Nail/hair Joint/bones Respiratory
Infiltrated Yellow-wax colour Dry hair, loss Striated friable nails Difuse altralgia Bradipneea Pleural efusion HYPER Moist, warm, fine Pruritus Edema Soft hair, loss Nail destruction Osteoporosis with bone pain Scapulo-humeral periarthritis Tachypneea Skin Nail/hair Joint/bones Respiratory
11
Clinical Signs HYPO HYPER Cardio-vascular Digestiv Genital
Cardiomegaly Pericardial effusion Angor Macroglosia Meteorism/constipation Gallbladder diskinesia + stones ♀ amenorrea, abnormal bleedings, galactorea, frigidity ♂ sterility, impotence Intelectual deficit Memory problems Depression Carpian canal syndrome HYPER Tachycardia/arithmia Heart failure Abnormal sounds Incresed apetite Weight loss Hypermotility + Diarrhea ♀ oligo/amenorrea ♂ gynecomastia, impotence Fatigue Nervousness Fine tremour extremities Cardio-vascular Digestiv Genital Nervous system
12
Clinica Signs- local compression
Nervous structures Laryngeal recurrent nerve – butonal voice Cervical sympathetic chain (Claude-Bernard-Horner syndrome) = enoftalmia, miozis, congestion of half of the face) Hipoglosal nerve – deviation of the tong on anterior projection Frenic (hickup), spinal (palsy of SCM and trapezius), Vagus (digestive changes); Vascular: venous (venous ectasia) arterial (cerebral irrigation) Esofagus: disphagia Trachea: dispnoea, radiologic changes – deviation of the trachea (mostly lateral deviation)
13
Goiter – simple/non-toxic
Iodine deficit Symptomes None →compresion signs Paraclinical T3, T4; TSH Echo, CT, RMN, ENT exploration
14
Goiter - simple SCINTIGRAM
15
Diagnostic – organ of origin :
Thyroid in clinical examination – all signs Scintigrafy - I131 capture in tumor . Diagnostic - goiter Anamnesis – endemic area Clinical examination: caracteristics of tumor Paraclinical examination - imagistics Diagnostic - functional Thyroid hormonal function
16
Differential diagnostic
Cervica tumors: Thyreoglotic cyst Dermoid tumors / Branchial arch derived tumors Cervical adenopatht Benign tumors: lipoma, sebaceus cysts, angioma Malignant tumors Hodgkin, LN, sracomas Other thyroid diseases Funcţional hypertrophy (puberty, gestational, menstruation) Acute thyroiditis Subacute thyroiditis - de Quervain Chronic lymphocytic thyroiditis – Hashimoto Riedl chornic thyroiditis Specific chronic thyroiditis: sifilis, tbc, actinomicosis Hipertrofy associated to hyperthyroidism thyreotoxic syndrome Thyroid cancer
17
Abnormal positions Ectopic goiter
Intrathoracic goiter: abnormal thyroid tissue developed in the thorax – vasculature from thoracic cavity Lateral cervical goiter: abnormal thiroid tissue developed in the lateral cervical area Lingual – defect in migration of tissues in emriogenesis: the thyroid gland is stuck at the level of foramen cecum Intratracheal goiter: first segments: produces obstruction Intraesophageal goiter: rarity ~ esophageal tumor Ovarina goiter: abnormal thyroid tissue in the ovary (disembrioplastic/metastasis) Cervical-mediastinal goiter: cervical origin but aspirated in the upper part of thoracic cavity: feeding vessels are normal from cervical sources.
18
Treatment L-THYROXINE IODINE THERAPY RADIO-IODINE THERAPY SURGERY
50% reduction in volume in 30% of cases IODINE THERAPY RADIO-IODINE THERAPY 50-60% reduction in ~1-1.5 y SURGERY Tiroidectomy subtotal/total + L-Thyroxine
19
Surgical treatment – WHEN?
Failure of other modalities Multinodular goiter or cold nodules on scintigrafy Goiter with lesions which are most probably irreversible: fibrosis, recurrent cysts) Complicated goiter: hyperthyroidism, inflammation, intracystic bleeding, compression syndrome Esthetic indications
20
THYROTOXICOSIS Hypermetabolic condition characterised by increased levels of FT3 and/or FT4 Hyperthyroidism Subacute thyroiditis Exogenous administration of thyroid hormones
21
HYPERTHYROIDISM Excess synthesis and discharge of hormones in the circulation Graves 50-60% Autoimune condition Multinodular goiter 15-20% Long lasting goiter Toxic adenoma 3-5%
22
PATHOGENY Graves Disease
Ig G acting aginst Thyroid gland , including effect against TSH receptor in a stimulatory fashion: activation of cAMP = increase the volume of the gland, vascular pattern and hypersecretion of thyroid hormones. LATS - Long Acting Thyroid Stimulator TSI - Thyroid Stimulating Immunoglobulins Nodular Goiter associated with hyperthyroidism: Nodules producing high levels of hormone secretion Toxic adenoma: Thyroid nodule completely independent (bening in majority of cases) without feed back inhibition = administration of T3/T4 does not produce suppression.
23
HYPERTHYROIDISM Neurological problems Fine tremour Exophthalmia
Neurovegetative imbalance: Excessive sweetening Low level fever Thyroid hypertrophy Hyperthyroidism syndrome depending on T3/T4 levels
24
HYPERTHYROIDISM Skin Warm, fine, moist, intense dermographism Nails
Thin, fragile Infiltrative demopathy Pretibial mixedema Thyrotoxic myopathy Loss of muscular mass Hypotonia Muscular pain Fatigue All systems are affected Cardiovascular Respirator Digestiv Genital
25
HIPERTHYROIDISM LAB SCINTIGRAPHY Increased RIC Imaging the gland
Low TSH High FT3, FT4 TSI, LATS SCINTIGRAPHY Increased RIC Imaging the gland Ultrasound CT RMN FNA
26
TREATMENT Iodine – Lugol solution Corticosteroizii
Symptomatic treatment: Beta-blockers Sedatives Inhibitors of hormone synthesis- synthetic antithyroid drugs (propiltiouracil, methimazol, carbimazol) Block the oxidation of iodine with sequential block in iodothyrozine synthesis Produces a secondary goiter development due to rises in TSH Normal thyroid hormone levels in weeks Major side effects: Agranulocitosis, liver toxicity, LES, alopecia, nefrotic syndrome, poliarthritis, poliradiculonevritis. Iodine – Lugol solution Reduce the volume and vascular pattern of the thyroid gland. Effect is maximal in 10 days, maintained 2-3 weeks, then the gland escapes suppresion. Preopertaive or in thyrotoxicosis associated with syntehetic antithyroid drugs. Corticosteroizii Lower T secretion Inhance urinary loss Prevent and treat thyrotoxicosis cresc ioduria RADIOACTIV IODINE Thyroid tissue destruction – aiming to transform all patients in hypothyroid patients.
27
TREATMENT SURGERY THYROIDECTOMY: subtotal, quasitotal, total
Correct preoperative preparation – normal thyroid hormone levels + sedation Postoperative complications Hemorrhage Thyrotoxic crises Recurrent nerve palsy Hypoparathyroidism
28
THYROTOXIC CRISIS – major emergency
Acute augmentation of hyperthyroid status May develop in the first hours postoperative, more often after incomplete preparation Stage I : tachicardia >130/minute, hiperthermia, massive sweating, dehydration, intense tremour. Stage II: adds desorientation, stupor and somnolence. Stage III: coma Treatment: Large doses of synthetic antithyroid drugs Mineral iodine (KCl or Lugol) Symptomatic treatment: corticoids and beta-blockers Lower body temperature – refrigeration Intensive care: O2, ionic balance
29
INFLAMMATORY DISEASES = THYROIDITIS
30
Classification ACUTE SUBACUTE – granulomatous DeQuervain CHRONIC
Nonspecific Limfocytic Hashimoto Fibrotic Riedel Specific TBC, sifilis, actinomycosis
31
ACUTE THYROIDITIS PATHOGENY
<1% of all thyroid pathology, frequently preexisting goiter PATHOGENY Germes – abscess formation (aggressive germs + low immunity) Bacteria – streptococcus, stafilococcus, pneumococcus, G-bacili Viruses – influenza, Fungs: – Candida Parazitic Contamination: Hematogenous, lymfatic, direct Source Close contact Distant source with hematogenic circulation
32
CLINICAL EXAMINATION Anamnesis Clinical examination Sudden onset
Local inflammatory signs Fever high ( ), chills and tachicardia Anterior cervical pain Pressure sensation Radiating: mandible, ear Intensifies with swallowing Antalgic position Dysphagia Dyspnoea Dysphonia Irritative coughing Clinical examination T gland enlarged (whoe or part) and very painful All inflammatory signs in the anterior cervical area (skin) Abscess formation can produce fluctuence. Inflammatory LN in the latero-cervical area
33
LAB EVALUATION High WBC with % PMN Vey high ESR
Thyroid scintigram: a cold difuse area (no iodine capture) US: hypoecoic i the begining, transsonic if absecess is formed. Blood cultures – isolation of bacteria RIC may be normal/lower then normal. In cases of abscess: puncture and culture of pathogenic germ
34
TREATMENT Prognostic: very good if rapidly diagnosed and treatment is adequate Complications without proper treatment: Septic: local (mediastinitis, fistula formation – skin, esophagus, trachea), or metastatic. Mechanic: large abscess behaves like a tumor Vascular: thrombosis of adjacent veins Endocrine: very unusual
35
TREATMENT - early Medical Surgical Antibiotics: empirical + cultures
NSAID Antialgic medication Surgical Abscess – drainage Partial thyroidectomy +/-
36
Granulomatous thyroiditis DeQuervain thyroiditis
SUBACUTE THYROIDITIS Granulomatous thyroiditis DeQuervain thyroiditis
37
PATHOGENY 5% of all T pathology F>M 20 – 40y Ethiology
unknown Known: Viral (urlian, influenza) Bacteria (streptococcus, entorobacteriacea) Genetic predisposition Pathogeni: destruction of folicular epithelium: Immediate release of thryoid hormones Lowers capacity to produce hormones in time
38
Pathological changes Macroscopic Mycroscopic
T is increased in size (2-3x), harder, yelowish Mycroscopic Multifocal granulomatous inflammatory reaction, limfocityc and plasma cells infiltration + interstitial
39
DIAGNOSTIC Past medical history: Anamnesis Clinical evaluation
50% cases 2-6 weeks before respiratory infection, rhinopharinx, sometimes easy to forget about. Anamnesis +/- Sudden onset Fever (High), chills, malaise Cervical pain aggravated by swallowing, cough and head movements. Clinical evaluation T gland enlarged, asymetrical, ferm and painful. No palpable LN Signs of moderate hyperthyroidism in 20% of cases
40
LAB EVALUATION High WBC – lymphocites High ESR
High T3 – T4, thyroglobulin in early stages of inflammation, while TSH and RIC are diminished. Increses levels of antyT antibody ~3 weeks after onset. US – diffuse hypoechigenity Scintigram – inhomogeneous fixation with cold areas, but will become normal with healing Gigantic multinuclear cells on FAC
41
DIAGNOSTIC Acute thyroiditis Hashimoto Graves Carcinoma POZITIV Pain
Local and general inflammatory signs Very low RIC Cytology antyT antibody Differential Acute thyroiditis Hashimoto Graves Carcinoma
42
PROGRESSION Self healing condition Transform in chronic inflammation
1-3 months No sequels Transform in chronic inflammation Riedel/ Hashimoto Hipothiroidism - 10% Recurrent condition – very rare
43
TREATMENT NSAID/ CORTICOSTEROIDS Hormonal – hyper or hypo function
Surgical – an exception Lobectomy, thyroidectomy When a nodular hypertrophy persists
44
CRONIC LYMPHOCYTIC THYROIDITIS
Hashimoto thyroiditis
45
PATHOGENY The most common type of inflammatory disease of T gland
The most common cause of hypothyroidism F>B; 40-50y CAUSE Autoimmune aggression: ATB against Thyroglubuline, Mycrosomes.
46
Histology MACRO MICRO Hypertrophy with accentuated lobulation
Ferm, pale, grey, reduced vascular pattern. MICRO Lymphocytic infiltration– even formation of germinative centers Follicular epithelium destruction – large oxiphilic cells Askenazy cells (diagnostic) Fibrosis
47
PRESENTATION GOITER Past medical history:
Other autoimmune diseases (LES, rheumatoid arthritis, dermatomiositis) GOITER Insidious onset Not very large Difuse, asymmetrical, no signs of compression Thyroid function can be high, normal or low Fatigue
48
LAB WORK Nonspecific inflammatory reaction (normal WBC, increased ESR)
Immunology Antimicrosomal antibodies 100% Antithyroglobulin antibodie 90% i Thyroid function Initial: hyperfunction without increased production (RIC increased, basal metabolism increased) Late: hypofunctiondue to destruction of parenchime (RIC bellow normal, decresed basal metabolism)
49
DIAGNOSTIC POZITIV DIFFERENTIAL Goiter Antibodies + biopsy
Clinical – can mimic anything DeQuervain Cancer
50
COMPLICATIONS PROGNOSTIC Hypothyroidism – 50-80%
Slow progression with periods of long stagnation (years) followed y progression Rapid progression - unusual
51
TREATMENT Hormonal Surgical Hormonal replacement Compression
Questionable diagnostic (Lymphoma/Cancer)
52
Riedel wood-hard thyroiditis
FIBROTIC THYROIDITIS Riedel wood-hard thyroiditis
53
PATHOGENY Chronic inflammation with fibrotic transformation of T gland and surrounding tissue Can be associated with other fibrotic diseases: Retroperitoneal fibrosis Mediastinal fibrosis Parotid gland fibrosis, salivary/lacrimal gland fibrosis Sclerosing cholangitis HLA-DR3 – genetic determination Antimicrosomal antibodies : autoimmune mechanism Mycroscopy: fibrosis + lymphocytic infiltration Unknown cause Final stage of any autoimmune thyroiditis.
54
PATHOLOGY One lobe or whole gland Fibrotic, white tissue
Fibrosis extends outside T gland: there are no cleavage plans and structures can not be identified
55
CLINICAL PRESENTATION
Females: 30-60y age Anamnesis signs of diffuse hypertrophy + compression of adjacent organs Clinical examination wood-hard consistency Tender T gland fixed to all plans T gland does not invade skin Hormonal status: normal (most cases) or hypo
56
LAB WORK Slight inflammatory response Normal or low T hormones
Sometimes: low levels of antyThyroid antibodies US: hypoechoic + invasion in adjacent structures Scintigram: inhomogenous fixation with areas with non-fixation of iodine
57
DIAGNOSTIC Pozitiv: pathologic examination Differential COMPLICATIONS
cancer Hashimoto DeQuervain COMPLICATIONS Compression Progression Very slow: years until compression is significant
58
TREATMENT Hormonal Surgical Replacement for hypothyroidism
May reduce progression to fibrosis Surgical Thyroidectomy Limited excision for decompression
59
THYROID CANCER
60
MOST COMMON ENDOCRINE CANCER
1% OF ALL CANCERS Occurs mainly in patients years Annual incidence new cases/106 Annual mortality ~4/106 Most carcinomas – favorable prognosis Necroptic incedence much higher and with significant variations: USA ~1.8%; Honolulu~15%; Hiroshima 25%
61
RISK FACTORS Iodine supplements increase the incidence of papillary carcinoma (<T, well differentiated, overall increases survival) External irradiation in human the only proven carcinogenic factor for thyroid carcinoma children with neck irradiation develop papillary carcinoma
62
RISK FACTORS 1986 Cernobil effect- steady increase (Pacini 1997)
Peak 3x in ; ~80% children <14 years of age
63
PATHOLOGY - follicular cells-
HYPOFUNCTIONAL ADENOMA FOLLICULAR CARCINOMA FOLlICULAR CELLS ANAPLASTIC CARCINOMA PAPILLARY CARCINOMA HYPERFUNCTIONAL ADENOMA
64
PATHOLOGY essential in classification
Papillary carcinoma 80% from follicular cells usually well differentiated but very frequently multifocal mixed forms are included slow growing – excellent prognosis Spreading: tends to spread locally into lymph nodes and adjacent structures
65
PATHOLOGY Invasion in the local lymph nodes is not associated with a worse prognosis Poor prognosis: Male gender >50 years Less differentiated Metastases: lungs, rarely to bones Tumors larger then 4 cm Local invasion or distant metastases
66
PATHOLOGY Follicular carcinoma 10% from follicular cells
HIGHER FREQUENCY IN IODINE DEFICIENT AREAS from follicular cells usually well differentiated slow growing – good prognosis closely resemble folicular adenomas capsular and/or vascular invasion is defining the malignant status tends to take up radioactive iodine. 10% chance of being multifocal.
67
PATHOLOGY Spreading: tends to spread through the blood stream making it more difficult to control and also grows into adjacent structures. Metastases lung and bone usually concentrate iodine Poor prognosis associated with: Age >45 years Local extracapsular invasion Distant metastases
68
PATHOLOGY Hürthle Cell carcinoma 3.6%
composed of "modified follicular cells" very similar to follicular carcinoma 25% chance of being multifocal does not tend to take up radioactive iodine has a prognosis similar to that of follicular carcinoma.
69
PATHOLOGY Medullary carcinoma 2.7% from the parafollicular C cells
There are two types Genetic disposition – AD MUTATIONS- represents about 20% of all patients with medullary carcinoma USUALLY PRESENT IN BOTH LOBES Sporadic – occurs randomly and represents 80% of medullary carcinoma USUALLY PRESENTS UNILATERAL
70
PATHOLOGY - CMT Worse prognosis compared with previous forms: 50% survive at 10 years Occult tumors discovered in families at risk – 95% cure rate Detection by screening for calcitonin basal and/or pentagastrin infusion test TUMOR PRESUMED – 95% cure TUMOR PALPABLE – 17% cure SPREADING: blood born metastases and lymphnodes
71
PATHOLOGY Anaplastic carcinoma 1.7%
develops from follicular cells poorly differentiated aggressive and rapidly growing. poor prognosis <2 years Spreading: rapidly in the adjacent structures and also sends blood born metastasis – STAGE IV Others rare tumors that may develop in the thyroid gland are Lymphoma Sarcoma – originating in the connective tissue Carcinosarcoma - composed of both malignant thyroid cells and connective tissue Metastatic tumors
72
SIGNIFICANT MICROSCOPIC FEATURES
Differentiation level Capsular or vascular invasion (in follicular and Hürthle cell carcinomas invasion is needed to prove the tumor malignant Regional lymph node involvement 4. Invasion of adjacent structures (extracapsular invasion)
73
DIAGNOSTIC clinical examination
Evaluation of the neck NODULE Assesment of nodules Firmness Mobility Multiple Evaluation of typical metastatic sites Cervical nodes Bones Lungs
74
DIAGNOSTIC anatomical evaluation
ULTRASOUND SCAN Confirm - thyroid gland Solid/cystic Unic/multicentric Lymphnodes Guides FNB Doppler NON INVASIVE - SCREENING
75
DIAGNOSTIC anatomical test
Scintiscan: Evaluate the capacity to concentrate iodine Cold nodules – 15-20% are malignant Essential in postoperative follow-up Estimate the remnant thyroid tissue Diagnose iodine concentrating metastatic tumor WBS - Diagnose bone metastases
76
DIAGNOSTIC anatomical test
CAT scan and chest X-Ray Lung metastases Restrosternal goiters
77
FUNCTIONAL EVALUATION
Is mostly used in the follow-up Thyroglobuline >5ng/ml after total thyroidectomy >10ng/ml after total thyroidectomy Calcitonine (Pg-CT) marker for the diagnosis of MTC in high risk populations (nodule + CT(+) the most significant association) Marker for postoperative follow-up
78
CYTOLOGIC DIAGNOSIS Fine needle aspiration cytology – most important study in evaluating thyroid nodules Core biopsy – larger sample but higher risk HISTOLOGIC DIAGNOSIS Preoperative diagnosis of most thyroid cancers Help to plan the extent of surgical resection Selection of cases which will not benefit from surgical management
79
CYTOLOGIC DIAGNOSIS Results Nondiagnostic Indeterminate Malignant
80
GENETIC STUDIES Numerous mutations are associated with thyroid cancer
MTC Germinal cells RET mutations associated with early onset and multicentric tumors MEN II (A and B) Profilactic thyroidectomy
81
SURGICAL RESECTION IS THE STANDARD THERAPY
TREATMENT SURGICAL RESECTION IS THE STANDARD THERAPY
82
EXTENT OF SURGICAL RESECTION
Depends primarily on HISTOLOGICAL type Age Capsular/extracapsular invasion Invasion in adjacent structures ESSENTIAL – PREOPERATIVE ACCURATE DIAGNOSIS – FNB AND INTRAOPERATIVE FROZEN SECTIONS
83
SURGICAL TREATMENT PAPILLARY CARCINOMA CONSERVATIVE
Lobectomy +/- istmusectomy Macroscopic - unic nodule Permanent TSH supression is essential Acceptable if poor prognostic factors ar absent 5-10% will develop recurrences
84
SURGICAL TREATMENT PAPILLARY CARCINOMA AGGRESSIVE APPROACH
Near total/total thyroidectomy For macroscopic multifocal + lymph-nodes involvement Lymph-node dissection – primary drainage arrea
85
SURGICAL TREATMENT FOLLICULAR CARCINOMA
Dg. suspected on FNB and CONFIRMED on frozen section Total/near total thyroidectomy Total thyroidectomy makes metastases visible 5-10% recur in residual tissue
86
SURGICAL TREATMENT ANAPLASTIC TUMORS
Old age patients– usually is of no benefit Middle age – total thyoidectomy may be tried, but little benefit Istmusectomy – pressure on the trachea (similar results with radiotherapy) 1 year survival rate ~0
87
SURGICAL TREATMENT MEDULLARY CARCINOMA
Total thyroidectomy Frequent multicentric (both forms) Lymphadenectomy in the primary drainage area – essential. 75% of cases demonstrate MTS in nodes from the central compartment Nodes in the secondary drainage area should be sampled - if involved RADICAL NECK DISSECTION Pheocromocytoma and parathyroid tumors should be checked and solved prior to total thyroidectomy
88
COMPLICATIONS recurrent laryngeal nerve damage 2-8%
permanent hypoparathyroidism 1-3% ; 5-10% in difficult resections hematoma formation wound infection keloid formation in the scar airway compromise (anaplastic carcinoma)
89
POSTOPERATIVE TREATMENT
radioactive iodine thyroid suppression external radiotherapy (exceptional) – locally advanced papillary carcinoma and metastatic sites external beam radiotherapy cytotoxic chemotherapy
90
FOLLOW-UP Differentiated carcinomas thyroglobulin measurement + WBS
Medullary carcinoma - calcitonin
91
OVERALL PROGNOSIS IS GOOD WITH > 94% LONG TERM SURVIVAL
92
PARATHYROID GLANDS
93
Disorders of the Parathyroid Glands
Maintenance of calcium, phosphate and magnesium homeostasis is under the influence of two polypeptide hormones; * parathyroid hormone(PTH) * calcitonin (CT), * sterol hormone, 1,25 dihydroxy cholecalciferol (1,25 (OH)2D3.
94
Parathyroid Glands These hormones regulate the flow of minerals in and out of the extracellular fluid compartments through their actions on intestine, kidneys, and bones.
95
Normal function The PTH acts directly on the bones and kidneys and indirectly on the intestine through its effect on the synthesis of 1,25 (OH)2D3. Its production is regulated by the concentration of serum ionized calcium. Lowering of the serum calcium levels will induce an increased rate of parathyroid hormone secretion
96
Normal function Calcitonin is released by the “C” cells (parafollicular cells in the thyroid gland) Secretion in response to small increases in plasma ionic calcium. It acts on the kidney and bones to restore the level of calcium PTH and calcitonin are antagonistic
97
Disorders of the Parathyroid Function
Primary Hyperparathyroidism Excessive PTH from one/more glands which are hyperfunctional. HyperCa that fails to inhibit in normal feed-back loop. Cause? – possible genetic (multiple adenomas are frequent) . Carcinoma<1%
98
Clinical Features Kidneys: renal stones or nephrocalcinosis (diffuse deposition of CaPO4. Skeleton: osteitis fibrosa cystica Massive subperiostal resorbtion of bone Bone cysts and brown tumors of long bones Other: muscle weakness, easy fatigability, peptic ulcer disease, pancreatitis, hypertension, gout and pseudogout as well as anemia and depression 90% cases diagnosed before that on screening for calcium
99
Diagnosis hypercalcaemia in more than one serum measuremen
elevated immunoreactive PTH is characteristic (iPTH)
100
LAB Work Serum phosphate is usually low but may be normal.
Hypercalcaemia is common alkaline phosphatase (of bone origin)- high urinary hydroxyproline concentrations are commonly elevated when the bones are involved. Negative glucocoticoid supression test (supression indicates no adenoma)
101
RADIOLOGY subperiosteal bone resorption usually on the radial surfacy of the distal phalanx with distal phalangeal tufting cysts formation and generalized osteopenia.
102
Pre-operative localization of the abnormal parathyroid gland(s):
Ultrasonography MRI CT Thallium 201 – Tehcnichum99m scan (subtraction study)
103
Treatment Very often “biochemical” hyperPTH.
Resection of the parathyroid lesion is curative with recurrences observed mainly in the multiple glandular disease. Tumor 31/2 of all hyperplastic tissue Medical management of hypercalcemia Glucocorticoids - Diuresis Mithramycin - Calcitonin Bisphosphonates - Phosphates Estrogen
104
Secondary hyperparathyroidism
chronic stimulation of the parathyroid glands by a chronic decrease in the ionic calcium level in the blood
105
Major causes Dietary deficiency of vitamin D or calcium
Decreased intestinal absorption of vitamin D or calcium due to primary small bowel disease, short bowel syndrome, and post-gastrectomy syndrome. Drugs that cause rickets or osteomalacia such as phenytoin, phenobarbital, cholestyramine, and laxative.
106
Major causes of chronic hypocalcemia
States of tissue resistance to vitamin D Excessive intake of inorganic phosphate compunds Psudohypoparathyroidism Severe hypomagnesemia Chronic renal failure
107
Hypoparathyroidism Deficient secretion of PTH which manifests itself biochemically by hypocalcemia, hyperphospatemia diminished or absent circulating iPTH and clinically the symptoms of neuromuscular hyperactivity.
108
Surgical hypoparathyroidism – the commonest
Causes: Surgical hypoparathyroidism – the commonest Idiopathic hypoparathyroidism Genetic Autoimmune Functional (associated with hypoMg – PTH can not be released in this condition)
109
Clinical features Neuromuscular: Cardiovascular Cataract
Dental problems Malabsorbtion Paresthesia Tetany Hyperventilation Adrenergic symptoms Convulsion Signs of latent tetany Prolonged QT interval in the ECG Resistance to digitalis Hypotension Refractory heart failure
110
Diagnosis In the absence of renal failure
hypocalcaemia with hyperphosphataemia is virtually diagnostic of hypoparathyroidism. Undetectable serum iPTH confirms the diagnosis or it can be detectable if the assay is very sensitive.
111
TREATMENT Prevention – surgical trauma
Oral calcium with pharmacological doses of vitamin D or its potent analogues. Phosphate restriction in diet may also be useful with or without aluminum hydroxide gel to lower serum phosphate level.
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.